Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Karl Swedberg

Showing results (281-290 of 471) with videos related to

Pageof 48
Sort By:
European Journal of Heart Failure|May 16, 2014
Baseline characteristics and treatment of patients in prospective comparison of ARNI with ACEI to determine impact on global mortality and morbidity in heart failure trial (PARADIGM-HF)John J V McMurray, Milton Packer, Akshay S Desai, et al.
European Journal of Heart Failure|June 11, 2016
Efficacy of sacubitril/valsartan vs. enalapril at lower than target doses in heart failure with reduced ejection fraction: the PARADIGM-HF trialOrly Vardeny, Brian Claggett, Milton Packer, et al.
European Journal of Heart Failure|January 28, 2014
The relationship between left ventricular ejection fraction and mortality in patients with acute heart failure: insights from the ASCEND-HF TrialMustafa Toma, Justin A Ezekowitz, Jeffrey A Bakal, et al.
European Journal of Heart Failure|August 25, 2007
Effect of carvedilol and metoprolol on the mode of death in patients with heart failureWillem J Remme, John G Cleland, Leif Erhardt, et al.
Clinical Research in Cardiology : Official Journal of the German Cardiac Society|October 6, 2021
Growth differentiation factor 15 predicts poor prognosis in patients with heart failure and reduced ejection fraction and anemia: results from RED-HFThor Ueland, Lars Gullestad, Lei Kou, et al.
European Heart Journal|October 26, 2012
Predicting survival in heart failure: a risk score based on 39 372 patients from 30 studiesStuart J Pocock, Cono A Ariti, John J V McMurray, et al.
Cardiovascular Drugs and Therapy|May 27, 2004
A description of the clinical characteristics at baseline of patients recruited into the Carvedilol or Metoprolol European Trial (COMET)John G F Cleland, Kevin Goode, Leif Erhardt, et al.
Journal of the American College of Cardiology|May 13, 2024
Mineralocorticoid Receptor Antagonists in Patients With Heart Failure and Impaired Renal FunctionShingo Matsumoto, Alasdair D Henderson, Li Shen, et al.
Journal of the American College of Cardiology|March 9, 2019
B-Type Natriuretic Peptide During Treatment With Sacubitril/Valsartan: The PARADIGM-HF TrialPeder Langeland Myhre, Muthiah Vaduganathan, Brian Claggett, et al.
European Journal of Heart Failure|October 13, 2012
Association between diabetes mellitus and post-discharge outcomes in patients hospitalized with heart failure: findings from the EVEREST trialSatyam Sarma, Robert J Mentz, Mary J Kwasny, et al.
Pageof 48

Showing results (281-290 of 471) with videos related to

Sort By:
Pageof 48
European Journal of Heart Failure|May 16, 2014
Baseline characteristics and treatment of patients in prospective comparison of ARNI with ACEI to determine impact on global mortality and morbidity in heart failure trial (PARADIGM-HF)John J V McMurray, Milton Packer, Akshay S Desai, et al.
European Journal of Heart Failure|June 11, 2016
Efficacy of sacubitril/valsartan vs. enalapril at lower than target doses in heart failure with reduced ejection fraction: the PARADIGM-HF trialOrly Vardeny, Brian Claggett, Milton Packer, et al.
European Journal of Heart Failure|January 28, 2014
The relationship between left ventricular ejection fraction and mortality in patients with acute heart failure: insights from the ASCEND-HF TrialMustafa Toma, Justin A Ezekowitz, Jeffrey A Bakal, et al.
European Journal of Heart Failure|August 25, 2007
Effect of carvedilol and metoprolol on the mode of death in patients with heart failureWillem J Remme, John G Cleland, Leif Erhardt, et al.
Clinical Research in Cardiology : Official Journal of the German Cardiac Society|October 6, 2021
Growth differentiation factor 15 predicts poor prognosis in patients with heart failure and reduced ejection fraction and anemia: results from RED-HFThor Ueland, Lars Gullestad, Lei Kou, et al.
European Heart Journal|October 26, 2012
Predicting survival in heart failure: a risk score based on 39 372 patients from 30 studiesStuart J Pocock, Cono A Ariti, John J V McMurray, et al.
Cardiovascular Drugs and Therapy|May 27, 2004
A description of the clinical characteristics at baseline of patients recruited into the Carvedilol or Metoprolol European Trial (COMET)John G F Cleland, Kevin Goode, Leif Erhardt, et al.
Journal of the American College of Cardiology|May 13, 2024
Mineralocorticoid Receptor Antagonists in Patients With Heart Failure and Impaired Renal FunctionShingo Matsumoto, Alasdair D Henderson, Li Shen, et al.
Journal of the American College of Cardiology|March 9, 2019
B-Type Natriuretic Peptide During Treatment With Sacubitril/Valsartan: The PARADIGM-HF TrialPeder Langeland Myhre, Muthiah Vaduganathan, Brian Claggett, et al.
European Journal of Heart Failure|October 13, 2012
Association between diabetes mellitus and post-discharge outcomes in patients hospitalized with heart failure: findings from the EVEREST trialSatyam Sarma, Robert J Mentz, Mary J Kwasny, et al.
Pageof 48